Scholarly Index
Karl D. Lewis
Regeneron (United States); 27,834 total citations; 268 total publications; best world rank #7
Regeneron (United States)
27,834Total citations
268Total publications
61H-index
Published ranking records
| Field | Window | World rank | National rank | Impact score |
|---|---|---|---|---|
| Nonmelanoma Skin Cancer Studies | Lifetime | 141 | US 60 | 98.30 |
| Melanoma and MAPK Pathways | Lifetime | 178 | US 97 | 97.96 |
| Hedgehog Signaling Pathway Studies | Lifetime | 167 | US 95 | 97.28 |
| Cancer Immunotherapy and Biomarkers | Lifetime | 983 | US 473 | 98.01 |
| CAR-T cell therapy research | Lifetime | 781 | US 453 | 97.94 |
| Cutaneous Melanoma Detection and Management | Lifetime | 390 | US 175 | 97.37 |
| Cancer and Skin Lesions | Lifetime | 653 | US 308 | 95.50 |
| Genetic and rare skin diseases. | Lifetime | 988 | US 339 | 83.66 |
| Hedgehog Signaling Pathway Studies | 2021-2025 | 7 | US 3 | 97.40 |
| Nonmelanoma Skin Cancer Studies | 2021-2025 | 59 | US 11 | 96.68 |
| CAR-T cell therapy research | 2021-2025 | 617 | US 340 | 96.31 |
| Melanoma and MAPK Pathways | 2021-2025 | 140 | US 41 | 92.80 |
| Cancer and Skin Lesions | 2021-2025 | 195 | US 73 | 85.62 |
| Genetic and rare skin diseases. | 2021-2025 | 223 | US 44 | 68.02 |
| Tumors and Oncological Cases | 2021-2025 | 825 | US 268 | 63.48 |